Skip to main content

Life Sciences is now live. See how →

Patent Examiner Lauren Quinlan Wells

Art Unit 1622 · Small-Molecule Drugs, Treatment Methods & Organic Synthesis · Tech Center 1600 · 344 applications filed 2021–2026

⚑ Very Hard · harder than 91% of examiners● Free examiner data

Lauren Quinlan Wells is a USPTO patent examiner in Art Unit 1622 (Small-Molecule Drugs, Treatment Methods & Organic Synthesis) with 344 applications from filing years 2021–2026. Examiner Wells's allowance rate is 47.2%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 91% of examiners. In 2021, decided applications with an examiner interview were allowed 71.8 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Very Hard
harder than 91% of examiners
Easier91st percentileHarder
Allowance rate vs peers
Examiner Wells47.2%
Art Unit 162271.3%
USPTO average82.2%
Allowance rate
47.2%
▼ USPTO avg 82.2%
Applications
344
filing years 2021–2026
First-action allowance
3.0%
patented with no rejection
Abandoned
30.2%
share of applications
Avg office actions
1.7
USPTO avg 1.3
Days to first OA
670
▲ USPTO 608
RCE rate
30.8%
USPTO 18.4%
Interview rate
33.7%
USPTO 26.2%

Examiner details

  • Art unit1622 · Small-Molecule Drugs, Treatment Methods & Organic Synthesis
  • Title / gradePatent Examiner · GS-13
  • Service5 years
  • PhoneOn each office action
  • In USPTO recordsWELLS, LAUREN QUINLAN
Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions

How to improve your odds with Examiner Wells

  • The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 31.6 to 79.4 points.
  • Plan for the timeline. First office action averages 670 days vs the 608-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (299), and applicants overcame it 32.5% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 4 measured years, by 16.6 to 33.3 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty137 issued · 50.5% overcome
§103 Obviousness299 issued · 32.5% overcome
§112 Definiteness & disclosure182 issued · 44.3% overcome
How applicants traverse §103 rejections🔒 Members

Applicants overcame 67 of the 206 decided §103 obviousness rejections from Examiner Wells in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Wells?

Draft your response with Examiner Wells's record and Art Unit 1622's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See how Boundly assists with office action responses.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Wells.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202413.8%83.3%66.7%+16.6pp
202329.7%80.0%50.0%+30.0pp
202245.0%64.3%37.5%+26.8pp
202141.9%57.9%24.6%+33.3pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/252843Substances for Treatment of HyperuricaemiaPatented1🔒 View
18/024831Composition Comprising Cannabinoids, and/or Terpens, and Methods of Using SamePatented2🔒 View
18/044964Methods of Treating Symptoms of Coronavirus InfectionAbandoned2🔒 View
17/978442Neutral Endopeptidase (NEP) and Human Soluble Endopeptidase (hSEP) Inhibitors for Prophylaxis and Treatment of Eye DiseasesPatented6🔒 View
See all 344 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1622 technology

Methods of treatmentPyrimidines & other diazinesKinase & enzyme inhibitorsOrganic synthesis processesTop CPC A61K · C07D · C07F
About this examiner. Lauren Quinlan Wells examines in Art Unit 1622 (Small-Molecule Drugs, Treatment Methods & Organic Synthesis, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Lauren Quinlan Wells's allowance rate?
Examiner Wells's allowance rate is 47.2%, compared with 82.2% across the USPTO and 71.3% in Art Unit 1622 for applications filed in the same years. That rate ranks Examiner Wells harder than 91% of examiners.
Is Examiner Wells a hard examiner?
Yes. Examiner Wells ranks harder than 91% of examiners, in the 91st difficulty percentile (very hard). Examiner Wells has a 47.2% allowance rate versus 82.2% across the USPTO and 71.3% in Art Unit 1622, 1.7 office actions per application versus 1.3, and an RCE rate of 30.8% versus 18.4% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Wells?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 4 measured years, by 31.6 to 79.4 percentage points. In 2021, 81.6% of decided applications with an interview were allowed, versus 9.8% of those without.
What is Examiner Wells's most common rejection?
§103 obviousness, issued 299 times in the data. Applicants overcame it 32.5% of the time.
Is an RCE worth filing with Examiner Wells?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 4 measured years, by 16.6 to 33.3 percentage points. In 2021, 57.9% of decided applications with an RCE were allowed, versus 24.6% of those without one.
How long until the first office action from Examiner Wells?
About 670 days on average, versus 608 days across the USPTO for applications filed in the same years.

Put Examiner Wells's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Lauren Quinlan Wells, or see an error? Request a correction.